Clindamycin Protects Nonhuman Primates Against Inhalational Anthrax But Does Not Enhance Reduction of Circulating Toxin Levels When Combined With Ciprofloxacin.

The Journal of Infectious Diseases
Nicholas J VietriArthur M Friedlander

Abstract

Inhalational anthrax is rare and clinical experience limited. Expert guidelines recommend treatment with combination antibiotics including protein synthesis-inhibitors to decrease toxin production and increase survival, although evidence is lacking. Rhesus macaques exposed to an aerosol of Bacillus anthracis spores were treated with ciprofloxacin, clindamycin, or ciprofloxacin + clindamycin after becoming bacteremic. Circulating anthrax lethal factor and protective antigen were quantitated pretreatment and 1.5 and 12 hours after beginning antibiotics. In the clindamycin group, 8 of 11 (73%) survived demonstrating its efficacy for the first time in inhalational anthrax, compared to 9 of 9 (100%) with ciprofloxacin, and 8 of 11 (73%) with ciprofloxacin + clindamycin. These differences were not statistically significant. There were no significant differences between groups in lethal factor or protective antigen levels from pretreatment to 12 hours after starting antibiotics. Animals that died after clindamycin had a greater incidence of meningitis compared to those given ciprofloxacin or ciprofloxacin + clindamycin, but numbers of animals were very low and no definitive conclusion could be reached. Treatment of inhalational anthra...Continue Reading

References

Feb 28, 1996·JAMA : the Journal of the American Medical Association·P A NuttingS Holcomb
Oct 25, 2002·Emerging Infectious Diseases·Daniel B JerniganUNKNOWN National Anthrax Epidemiologic Investigation Team
Sep 4, 1954·Lancet·H SMITHJ L STANLEY
Oct 21, 2004·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Allan R TunkelRichard J Whitley
Mar 29, 2005·Antimicrobial Agents and Chemotherapy·Abed AthamnaEthan Rubinstein
Apr 28, 2005·The Lancet Infectious Diseases·James J SejvarDavid S Stephens
Feb 24, 2006·Annals of Internal Medicine·Jon-Erik C HoltyDouglas K Owens
Jun 21, 2006·Applied Immunohistochemistry & Molecular Morphology : AIMM·Kathleen M TattiSherif R Zaki
Nov 7, 2006·Journal of Bacteriology·Ryan T CirzFloyd E Romesberg
Jun 30, 2009·Molecular Aspects of Medicine·Jean-Nicolas TournierCosima T Baldari
Sep 30, 2009·The Journal of Infectious Diseases·Alejandro Piris-GimenezPierre L Goossens
Jan 26, 2011·Antimicrobial Agents and Chemotherapy·Shay WeissZeev Altboum
Apr 27, 2011·Infection and Immunity·Celia M EbrahimiKelly S Doran
Jan 23, 2014·Emerging Infectious Diseases·Katherine A HendricksUNKNOWN Workgroup on Anthrax Clinical Guidelines
Jul 22, 2015·Annual Review of Microbiology·Mahtab MoayeriShihui Liu
Sep 24, 2015·Antimicrobial Agents and Chemotherapy·Shay WeissHaim Levy
Mar 22, 2016·Scientific Reports·Clémence RougeauxPierre L Goossens
Apr 12, 2016·Clinical Microbiology and Infection : the Official Publication of the European Society of Clinical Microbiology and Infectious Diseases·D van de BeekUNKNOWN ESCMID Study Group for Infections of the Brain (ESGIB)
Apr 18, 2018·Antimicrobial Agents and Chemotherapy·Amir Ben-ShmuelHaim Levy

❮ Previous
Next ❯

Related Concepts

Related Feeds

Anthrax Vaccines

Three different types of anthrax vaccines are available; a live-attenuated, an alum-precipitated cell-free filtrate and a protein recombinant vaccine. The effectiveness between the three is uncertain, but the live-attenuated have shown to reduce the risk of anthrax with low adverse events. Here is the latest research on anthrax vaccines.

Anthrax Vaccines (ASM)

Three different types of anthrax vaccines are available; a live-attenuated, an alum-precipitated cell-free filtrate and a protein recombinant vaccine. The effectiveness between the three is uncertain, but the live-attenuated have shown to reduce the risk of anthrax with low adverse events. Here is the latest research on anthrax vaccines.

Anthrax

Anthrax toxin, comprising protective antigen, lethal factor, and oedema factor, is the major virulence factor of Bacillus anthracis, an agent that causes high mortality in humans and animals. Here is the latest research on Anthrax.

Allen Institute for Brain Science Network

The Allen Institute for Brain Science Network is a not-for-profit biomedical research organization that provides open access to multiple neuroscience tools and resources. Find the latest research from tjr Allen Institute for Brain Science Network here.

Related Papers

Pediatrics in Review
Jacqueline Weingarten-Arams, Henry M Adam
Pediatrics in Review
M G Rosenberg
The Medical Clinics of North America
J L LeFrockR A Prince
The Medical Letter on Drugs and Therapeutics
© 2021 Meta ULC. All rights reserved